BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
During activation, T cells express receptors for receiving positive and negative costimulatory signals. Here we identify the B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. Crosslinking BTLA with antigen receptors induces its tyrosine phosphorylation and association with the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2). BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have increased specific antibody responses and enhanced sensitivity to experimental autoimmune encephalomyelitis. B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BTLA inhibits T/B cell activation and the secretion of cytokines11”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“anti-BTLA crosslinking may also cause the phosphorylation of the Src-homology domain 2 (SH2)-containing proteins tyrosine phosphatase-1 (SHP-1) and SHP-2 to activate suppression signaling”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“Additionally, the western blotting demonstrated that crosslinked BTLA promotes the phosphorylation of SHP-1/2, consistent with findings from previous studies11,42, and also activates the PI3K-Akt-GSK-3β pathway in purified CD4+ T cells.”
From BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion (2024) · cites this paper as [11]
In the citing paper
“BTLA is the essential co‐signaling immune checkpoint protein with bidirectional functions [331].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [331]
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
Self-citationPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“, and Y282 is similar to the immunoreceptor tyrosine-based switch motif (ITSM) in PD-1 (ref”
BackgroundDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Research works printed but not linked: 2
- Chambers, C.A. et al. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur. J. Immunol. 28, 3137–3143 (1998). · doi:10.1002/(sici)1521-4141(199810)28:10<3137::aid-immu3137>3.0.co;2-x
- Bachmann, M.F. et al. Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. Eur. J. Immunol. 31, 450–458 (2001). · DOI · Paper page
Cited by
Items 401–500 of 894
Annels, N. E., Simpson, G. R., Denyer, M., Arif, M., Coffey, M. C., Melcher, A. A., Harrington, K. J., Vile, R. G., & Pandha, H. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.09.010 · Cited by 32
The BTLA-HVEM complex – The future of cancer immunotherapy
Wojciechowicz, K., Spodzieja, M., & Wardowska, A. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116231 · Cited by 32
Truong, W., Plester, J. C., Hancock, W. W., Kaye, J., Merani, S., MURPHY, K. M. M., Murphy, T. L., Anderson, C. C., & Shapiro, A. M. J. (2007) · Transplantation · doi:10.1097/01.tp.0000289995.70390.20 · Cited by 30
“The negative co-signaling molecule B and T lymphocyte attenuator (BTLA) (4) is the newest member of the immunoglobulin superfamily, which includes coinhibitory receptors cytotoxic T lymphocyte antigen-4 (CTLA4) (5) and programmed cell death-1 (PD-1) (6).”
BackgroundResultSelf-citationdel Rio, M., Jones, N. D., Bühler, L. H., Norris, P. S., Shintani, Y., Ware, C. F., & Rodríguez-Barbosa, J.-I. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103698 · Cited by 30
Abudulai, L. N., Fernández, S., Corscadden, K. J., Hunter, M., Kirkham, L. S., Post, J. J., & French, M. A. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000869 · Cited by 30
Expression of the novel co-stimulatory molecule B7-H4 by renal tubular epithelial cells
Chen, Y., Yang, C., Xie, Z., Zou, L., Ruan, Z., Zhang, X., Tang, Y., Fei, L., Jia, Z., & Wu, Y. (2006) · Kidney International · doi:10.1038/sj.ki.5001867 · Cited by 30
Transplantation tolerance and its outcome during infections and inflammation
Chong, A. S., & Alegre, M. (2014) · Immunological Reviews · doi:10.1111/imr.12147 · Cited by 31
“Seminal observations of tolerance by Lenschow © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Immunological Reviews 258/2014 85 et al. (24) in a xenogeneic pancreatic islet transplantation Lin et al. (78) in a rat cardiac transplantation models using CTLA-4Ig, and by Larsen et al. (25) in allogeneic s…”
BackgroundInfluentialWatanabe, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105352 · Cited by 31
“can recruit the Src homology domain 2 (SH2)-containing protein tyrosine phosphatase1 (SHP1) and SHP2 [79].”
BackgroundB7-H4 transfection prolongs β-cell graft survival
Yuan, C.-L., Xu, J., Tong, J., Yang, H., He, F., Gong, Q., Xiong, P., Duan, L., Fang, M., Tan, Z., et al. (2009) · Transplant Immunology · doi:10.1016/j.trim.2009.03.007 · Cited by 29
T Cells and Costimulation in Cancer
Maj, T., Wei, S., Welling, T., & Zou, W. (2013) · The Cancer Journal · doi:10.1097/ppo.0000000000000002 · Cited by 30
Do inhibitory immune receptors play a role in the etiology of autoimmune disease?
Nordkamp, M. J. M. O., Koeleman, B. P. C., & Meyaard, L. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.11.007 · Cited by 30
Block, M. S., & Markovic, S. N. (2009) · American Journal of Immunology · doi:10.3844/ajisp.2009.29.49 · Cited by 32
“B and T Lymphocyte Attenuator (BTLA) is expressed upon T cell activation and Th1 (but not Th2) differentiation([125]).”
BackgroundT and B Cell Cooperation: A Dance of Life and Death
Bernard, A., Coitot, S., mont, A. B., & Bernard, G. (2005) · Transplantation · doi:10.1097/01.tp.0000153290.75695.31 · Cited by 28
Chung, J., Cruz, P. D., & Ariizumi, K. (2011) · European Journal of Immunology · doi:10.1002/eji.201041233 · Cited by 28
New B7 Family Members with Positive and Negative Costimulatory Function
Rietz, C., & Chen, L. (2003) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00303.x · Cited by 28
“However, so far, the only experiment suggesting that BTLA is a receptor for B7-H4 is the observation that B7xIg fusion protein binds to wild-type but not BTLAdeficient T cells (48).”
BackgroundCai, G., Nie, X., Li, L., Hu, L., Wu, B., Lin, J., Jiang, C., Wang, H., Wang, X., & Shen, Q. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0762-9 · Cited by 27
“A recently described receptor is B and T lymphocyte attenuator (BTLA), an immunoglobulin-like molecule belonging to the CD28 family, which is expressed by the majority of lymphocytes [11, 12].”
BackgroundRevesz, I. A., Joyce, P. M., Ebert, L. M., & Prestidge, C. A. (2024) · Clinical & Translational Immunology · doi:10.1002/cti2.1492 · Cited by 30
“55 Herpesvirus Entry Mediator (HVEM) is the natural ligand for BTLA and HVEM positive cells have been shown to inhibit V c 9V d 2 T-cell proliferation through interaction with BTLA.”
BackgroundCoinhibitory molecules in cancer biology and therapy
Mocellin, S., Benna, C., & Pilati, P. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.01.003 · Cited by 28
“BTLA (also known as CD272) is a type I membrane glycoprotein that has been recently identified as an inhibitory receptor (its cytoplasmic region presents two immunoreceptor tyrosine-based inhibitory motifs [ITIM]) with structural similarities to CTLA4 and PD1 [116].”
BackgroundSAP-Regulated T Cell–APC Adhesion and Ligation-Dependent and -Independent Ly108–CD3ζ Interactions
Chu, C., Wang, Y., Zhang, X., Ni, X., Cao, J., Xu, W., Dong, Z., Yuan, P., Wei, W., Ma, Y., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401660 · Cited by 27
Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding
Spodzieja, M., Kuncewicz, K., Sieradzan, A. K., Karczyńska, A. S., Iwaszkiewicz, J., Cesson, V., Wegrzyn, K. E., Zhukov, I., Maszota‐Zieleniak, M., Michielin, O. A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020636 · Cited by 32
“Several new compounds, such as antibodies and small molecules (including peptides and peptidomimetics) targeting PD-1 or CTLA-4 or its ligands, have been described in the literature [25,31].”
BackgroundXu, H., Cao, D., Guo, G., Ruan, Z., Wu, Y., & Chen, Y. (2012) · Diagnostic Pathology · doi:10.1186/1746-1596-7-142 · Cited by 27
“BTLA-deficient (BTLA−/−) mice are more sensitive to experimental autoimmune encephalomyelitis (EAE) [5], allergic airway inflammation This is an Open Access article distributed under the terms of the Creative ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and iginal work is properly cited.”
BackgroundInfluentialTargeting Costimulatory Pathways for Tumor Immunotherapy
Ward, R. C., & Kaufman, H. L. (2007) · International Reviews of Immunology · doi:10.1080/08830180701365941 · Cited by 27
“It is believed there are a number of redundant aspects between BTLA and PD-1 signaling, including the potential therapeutic efficacy of its blockade to enhance antitumor immunity [40].”
BackgroundCoinhibitory T-Cell Signaling in Islet Allograft Rejection and Tolerance
Truong, W., Hancock, W. W., Anderson, C. C., Merani, S., & Shapiro, A. M. J. (2006) · Cell Transplantation · doi:10.3727/000000006783982160 · Cited by 30
Hwang, H. J., Lee, J. J., Kang, S. H., Suh, J. K., Choi, E. S., Jang, S., Hwang, S., Koh, K., Im, H. J., & Kim, N. (2020) · Immunity Inflammation and Disease · doi:10.1002/iid3.390 · Cited by 27
“B‐ and T‐lymphocyte attenuator (BTLA), a member of the CD28 family, negatively regulates T cell activation as does PD‐1.(24) Both BTLA and PD‐1 contain Ig‐like domains that are expressed in T cells and B cells and present as monomers in T cells.”
BackgroundInfluentialPiotrowska, M., Spodzieja, M., Kuncewicz, K., Rodziewicz‐Motowidło, S., & Orlikowska, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113694 · Cited by 27
Cruz, D. G., Giri, R., Turro, D. G., Balsbaugh, J. L., Adler, A. J., & Rodríguez, A. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001188 · Cited by 31
Dendritic cell–regulatory T‐cell interactions control self‐directed immunity
Lange, C. M., Dürr, M., Doster, H., Melms, A., & Bischof, F. (2007) · Immunology and Cell Biology · doi:10.1038/sj.icb.7100088 · Cited by 31
Orchestrating Lymphocyte Polarity in Cognate Immune Cell–Cell Interactions
Bustos‐Morán, E., Blas‐Rus, N., Martin-Cofreces, N. B., & Sánchez‐Madrid, F. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.06.004 · Cited by 31
“BTLA interacts with HVEM (herpes virus entry mediator) expressed by the APC (Watanabe et al., 2003).”
BackgroundBourque, J., & Hawiger, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01163 · Cited by 26
“BTLA contains three immunoreceptor tyrosine-based inhibition motifs (ITIMs) which, upon phosphorylation, recruit Src homology domain 2 (SH2)-containing protein tyrosine phosphatases, SHP1 and SHP-2, which exert a variety of inhibitory effects within various lymphocytes (40, 41).”
BackgroundZhang, J., Zhang, H., Wang, Z., Yang, H., Chen, H., Cheng, H., Zhou, J., Zheng, M., Tan, R., & Gu, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-48520-7 · Cited by 27
Inhibitory costimulation and anti-tumor immunity
Martín‐Orozco, N., & Dong, C. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.003 · Cited by 26
“5 B- and T-lymphocyte attenuator—The B- and T-lymphocyte attenuator (BTLA), another member of the CD28 family, is expressed at very low levels on resting T cells and is upregulated on activated T cells [52].”
BackgroundInfluentialAschner, C. B., Loh, L. N., Galen, B. T., Delwel, I., Jangra, R. K., Garforth, S., Chandran, K., Almo, S. C., Jacobs, W. R., Ware, C. F., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aax2454 · Cited by 25
Identification of regulatory T cell molecules associated with severity of multiple sclerosis
Tapia-Maltos, M. A., Frenk, I. T., García-González, H. B., Rosetti, M., Barriga-Maldonado, V., Morales-Ramírez, F., López-Hernández, D., Rosetti, F., & Crispín, J. C. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520977045 · Cited by 25
Chung, J., Tomihari, M., Tamura, K., Kojima, T., Cruz, P. D., & Ariizumi, K. (2012) · Immunology · doi:10.1111/imm.12027 · Cited by 27
Autoimmune Therapies Targeting Costimulation and Emerging Trends in Multivalent Therapeutics
Chittasupho, C., Siahaan, T. J., Vines, C. M., & Berkland, C. J. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.60 · Cited by 28
Okano, M., Otsuki, N., Azuma, M., Fujiwara, T., Kariya, S., Sugata, Y., Higaki, T., Kino, K., Tanimoto, Y., Okubo, K., et al. (2008) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.03116.x · Cited by 27
Karabon, L., Partyka, A., Jasek, M., Lech‐Marańda, E., Grzybowska‐Izydorczyk, O., Bojarska-Junak, A. A., Pawlak, E., Tomkiewicz, A., Robak, T., Roliński, J., et al. (2016) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0430-x · Cited by 26
“T cells, B cells, NK T cells, NK cells, DCs and macrophages (Kobayashi et al. 2013; Watanabe et al. 2003).”
BackgroundŠedý, J. R., Balmert, M. O., Ware, B. C., Smith, W., Nemčovičová, I., Norris, P. S., Miller, B., Aivazian, D., & Ware, C. F. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.813295 · Cited by 27
3D Chromosomal Landscapes in Hematopoiesis and Immunity
Kloetgen, A., Thandapani, P., Tsirigos, A., & Aifantis, I. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.07.003 · Cited by 26
“The authors suggested that late-stage enhancer activation might potentially allow for chromatin contacts with nearby genes, such as BTLA, a gene responding to T cell activation with increased expression, and previously reported to be involved in attenuating T cell activation and immune responses [54].”
BackgroundPartyka, A., Tupikowski, K., Kołodziej, A., Zdrojowy, R., Hałoń, A., Małkiewicz, B., Dembowski, J., Frydecka, I., & Karabon, L. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.04.010 · Cited by 25
“It is also postulated that BTLA/HVEM interaction might be considered as another target in clinical immunotherapy [6].”
InfluentialSabado, R. L., Meseck, M. L., & Bhardwaj, N. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3387-7_44 · Cited by 24
Anticancer natural products targeting immune checkpoint protein network
Chun, K., Kim, D., Raut, P. K., & Surh, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.006 · Cited by 26
CD160 receptor in CLL: Current state and future avenues
Oumeslakht, L., Aziz, A.-I., Bensussan, A., & Mkaddem, S. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1028013 · Cited by 24
“The CD160-TM isoform binds less robustly to HVEM (5).”
BackgroundInfluentialPan, M., Zhao, H., Jin, R., Leung, P. S. C., & Shuai, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1156212 · Cited by 25
CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells
Thibult, M., Rivals, J., Mamessier, É., Gertner-Dardenne, J., Pastor, S., Speiser, D. E., Derré, L., & Olive, D. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0943-7 · Cited by 27
“The recently described inhibitory receptor B- and Tlymphocyte attenuator (BTLA, CD272) [2] is structurally and functionally related to CTLA-4 and PD-1 and is expressed by the majority of lymphocytes [2–4].”
BackgroundInfluentialRôle de CTLA-4 dans la cosignalisation négative du système immunitaire
Olive, D., le Thi, S., Xerri, L., Hirsch, I., & Nunès, J. A. (2011) · médecine/sciences · doi:10.1051/medsci/20112710012 · Cited by 27
Ye, L., Leslie, C., Jacques, A., Ardakani, N. M., Amanuel, B., & Millward, M. (2018) · Modern Pathology · doi:10.1038/s41379-018-0173-9 · Cited by 25
Hodkinson, B. P., Schäffer, M., Brody, J., Jurczak, W. J., Carpio, C. D. C., Ben‐Yehuda, D., Avivi, I. M., Forslund, A., Özcan, M., Alvarez, J. D., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100977 · Cited by 25
Liu, S., Wang, Y., Miao, C., Xing, Q., & Wang, Z. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01834-x · Cited by 26
CD160 and BTLA: LIGHTs out for CD4+ T cells
Kaye, J. (2008) · Nature Immunology · doi:10.1038/ni0208-122 · Cited by 24
Wang, W.-D., Gao, Y.-C., Lu, Y.-B., Zhang, J., Liu, G.-B., Kong, B., Xiang, W.-Y., Dai, Y.-C., Yu, S.-Y., Jia, Y., et al. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.09.015 · Cited by 24
Nielsen, M., Krarup‐Hansen, A., Hovgaard, D., Petersen, M. M., Loya, A. C., Westergaard, M. C. W., Svane, I. M., & Junker, N. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02568-x · Cited by 24
Demerle, C., Gorvel, L., Mello, M., Pastor, S., Degos, C., Zarubica, A., Rigotti, F., FIORE, F., Nunès, J. A., MALISSEN, B., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006348 · Cited by 23
Yuan, Y., Ling, H., Zhou, J., Liu, D., Ouyang, F., Chen, X., Long, S., Huang, Y.-S., Liu, X., Zheng, J., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110917 · Cited by 23
Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
Franzese, O., Torino, F., Fuggetta, M. P., Aquino, A., Roselli, M., Bonmassar, E., Giuliani, A., & D’Atri, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16335 · Cited by 23
“As described for CTLA-4 and PD-1, LAG-3 is essential for the extrinsic regulation of Treg homeostasis and development [161].”
BackgroundInfluentialHomo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design
Singh, S. S., & Jois, S. D. S. (2017) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2017.08.003 · Cited by 29
“Other members in this family include cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), CD152-inducible costimulator (ICOS) (Boomer & Green, 2010; Tezuka et al., 2000), programmed death receptor 1 (PD-1) (Ishida et al., 1992), and B- and T-lymphocyte attenuator (Watanabe et al., 2003).”
BackgroundRegulating regulatory T cells to achieve transplant tolerance.
Tao, R., & Hancock, W. W. (2007) · PubMed · Cited by 26
FORD, M., & Evavold, B. D. (2003) · Molecular Immunology · doi:10.1016/j.molimm.2003.11.004 · Cited by 24
Feng, X.-Y., Wen, X.-Z., TAN, X.-J., Hou, J.-H., Ding, Y., Wang, K.-F., Dong, J., Zhou, Z.-W., Chen, Y., & Zhang, X.-S. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2699 · Cited by 23
“Preclinical and clinical data indicate that the co-inhibitory receptors cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) are responsible for the suppression of human effector T cell responses to infectious diseases and cancer (10,11), and the therapeutic blockade of these two pat…”
InfluentialTransgenic Expression of CTLA-4 Controls Lymphoproliferation in IL-2-Deficient Mice
Hwang, K. W., Sweatt, W. B., Mashayekhi, M., Palucki, D. A., Sattar, H., Chuang, E., & Alegre, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5415 · Cited by 23
“This control is important to prevent progressive lymphoaccumulation, because mice deficient in Fas (6), CTLA-4 (7, 8), programmed death-1 (9, 10), and B and T lymphocyte attenuator (4) expression develop different degrees of lymphoaccumulation and autoimmunity.”
BackgroundThe LIGHT and DARC sides of herpesvirus entry mediator
Watts, T. H., & Gommerman, J. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506707102 · Cited by 23
Immune checkpoint blockade for cancer therapy: current progress and perspectives
Ye, H., Liao, W., Pan, J., Shi, Y. P., & Wang, Q. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2300492 · Cited by 27
“…and recruit SH2 domain-containing protein tyrosine phosphatase 1/2 (SHP1/2) to inhibit both TCR and CD28 signal ‐ ing after interacting with the cysteine-rich domain 1 (CRD1) region of HVEM, thus suppressing T cell function (Gavrieli et al., 2003; Watanabe et al., 2003; Sedy et al., 2005).”
InfluentialSignal Transduction Via Co-stimulatory and Co-inhibitory Receptors
Ogawa, S., & Abe, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_4 · Cited by 23
Cheng, T., Feng, Y., Chen, X., Zhou, J., & Song, Y. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112155 · Cited by 22
Wang, Y., Yang, S., Wan, L., Ling, W., Chen, H. H., & Wang, J. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5534 · Cited by 24
The Expression and Anatomical Distribution of BTLA and Its Ligand HVEM in Rheumatoid Synovium
Shang, Y., Guo, G., Cui, Q., Li, J., Ruan, Z., & Chen, Y. (2011) · Inflammation · doi:10.1007/s10753-011-9417-2 · Cited by 22
“BTLA is a member of the CD28 superfamily and characteristically displays two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic tail [5].”
InfluentialSelective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression
Paris, R., Petrovas, C., Ferrando‐Martínez, S., Moysi, E., Boswell, K. L., Archer, E. J., Yamamoto, T., Ambrozak, D. R., Casazza, J. P., Haubrich, R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144767 · Cited by 22
“We performed further CD4 T cell phenotypic analysis for the chemokine receptors CCR4, CCR5, CCR6, and CCR7 as well as the activation markers CD38, HLA-DR, and BTLA, a co-inhibitory receptor with functional characteristics similar to PD-1 and CTLA-4, which is increased among less differentiated T cells [25].”
MethodZhang, H., Wang, Z., Zhang, J., Gui, Z., Han, Z., Tao, J., Chen, H., Sun, L. Y., Fei, S., Yang, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.618737 · Cited by 22
“A newly found coinhibitory molecule, BTLA is expressed widely in innate and adaptive immunocytes and increases expression when activated (23).”
BackgroundHoff, H., & Brunner-Weinzierl, M. C. (2007) · European Journal of Immunology · doi:10.1002/eji.200636240 · Cited by 24
Regulation of T Cell Homeostasis by the Transmembrane Adaptor Protein SIT
Posevitz, V., Arndt, B., Krieger, T., Warnecke, N., Schraven, B. L., & Simeoni, L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1634 · Cited by 26
“E-mail address: luca.simeoni@med.ovgu.de Copyright © 2008 by The American Association of Immunologists, Inc. 0022-1767/08/$2.00 3 Abbreviations used in this paper: SIT, Src homology domain containing tyrosine phosphatase 2-interacting transmembrane adaptor protein; LAT, linker for activation of T cells; WT, wild type;…”
BackgroundInfluentialRegulation of Postsurgical Fibrosis by the Programmed Death-1 Inhibitory Pathway
Holsti, M. A., Chitnis, T., Panzo, R. J., Bronson, R. T., Yagita∥, H., Sayegh, M. H., & Tzianabos, A. O. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5774 · Cited by 25
“It should be noted that the recent characterization of the B and T lymphocyte attenuator, an inhibitory receptor structurally related to CTLA-4 and PD-1 (35), and its ligand of the B7 family, B7-H4/B7S1 (36, 37), indicates that other inhibitory receptors could well play a role in limiting adhesiogenesis.”
BackgroundRole of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
Mazloom, A., Ghalehsari, N., Gazivoda, V. P., Nimkar, N., Paul, S., Gregos, P., Rateshwar, J., & Khan, U. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082533 · Cited by 24
Liu, J., Ming, S., Song, W., Meng, X., Xiao, Q., Wu, M., Wu, Y., Xie, H., Zhou, J., Zhong, H., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107215 · Cited by 21
The Role of B and T Lymphocyte Attenuator in Respiratory System Diseases
Deng, Z. H., Zheng, Y., Cai, P., & Zheng, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635623 · Cited by 25
“(ITIM), and an immunoreceptor tyrosine-based switch motif (ITSM) (1, 6, 7).”
BackgroundInfluentialMultiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine
Rosa, D. S., Ribeiro, S. P., Fonseca, S. G., Almeida, R. R., Santana, V. C., Apostólico, J. D. S., Kalil, J. E., & Cunha‐Neto, E. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0101 · Cited by 22
“74,75 75–77 We designed a bicistronic plasmid driving the expression of HSV gD and HIVBr18 to immunize BALB/c mice.”
Costimulation: critical pathways in the immunologic regulation of asthma
Bellou, A., & Finn, P. W. (2005) · Current Allergy and Asthma Reports · doi:10.1007/s11882-005-0089-6 · Cited by 24
“Humoral responses to T cell–dependent antigens are enhanced in BTLA-deficient mice [ 35 ].”
BackgroundHan, L., Wang, W., Lu, J., Kong, F., Ma, G., Zhu, Y., Zhao, D., Zhu, J., Shuai, W., Zhou, Q., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.006 · Cited by 22
Targeting Dendritic Cell Function during Systemic Autoimmunity to Restore Tolerance
Mackern‐Oberti, J. P., Vega, F., Llanos, C., Bueno, S. M., & Kalergis, A. M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150916381 · Cited by 24
Yang, B., Huang, Z., Feng, W., Wei, W., Zhang, J., Liao, Y., Li, L., Liu, X., Wu, Z., Cai, B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155345 · Cited by 21
“BTLA is a transmembrane protein with two immunoreceptor tyrosine-based inhibitory motifs in its cytoplasmic tail [2].”
BackgroundInfluentialPedros, C., Altman, A., & Kong, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02412 · Cited by 22
“Btla −/− mice have elevated level of IgG in response to the T-cell dependent NP-KLH antigen (139).”
BackgroundD’Arrigo, P., Tufano, M., Rea, A., Vigorito, V., Novizio, N., Russo, S., Romano, M. F., & Romano, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181106114421 · Cited by 23
Aberrant Expressions of Co-stimulatory and Co-inhibitory Molecules in Autoimmune Diseases
He, W., Wang, B., Li, Q., Yao, Q., Jia, X., Song, R., Li, S., & Zhang, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00261 · Cited by 21
Huarte, E., Jun, S., Rynda‐Apple, A., Golden, S., Jackiw, L. O., Hoffman, C. A., Maddaloni, M., & Pascual, D. W. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501973 · Cited by 22
“mice developed a severe form of EAE (49), but adoptive transfer”
BackgroundResultMesri, M., Smithson, G. M., Ghatpande, A., Chapoval, A. I., Shenoy, S. G., Boldog, F. L., Hackett, C., Peña, C. E., Burgess, C., Bendele, A. M., et al. (2006) · International Immunology · doi:10.1093/intimm/dxh388 · Cited by 21
Antagonism between MyD88- and TRIF-dependent signals in B7RP-1 up-regulation
Zhou, Z., Hoebe, K. H. N., Du, X., Jiang, Z., Shamel, L., & Beutler, B. (2005) · European Journal of Immunology · doi:10.1002/eji.200525971 · Cited by 21
Wang, T., Zhang, J., Li, N., Li, M., Ma, S., Tan, S., Guo, X., Wang, Z., Wu, Z., Gao, L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.11.015 · Cited by 22
Plasmodium berghei-Released Factor, PbTIP, Modulates the Host Innate Immune Responses
Kalia, I., Anand, R., Quadiri, A., Bhattacharya, S., Sahoo, B., & Singh, A. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.699887 · Cited by 21
“BTLA displayed T-cell inhibition and was also a negative regulator of B-cell proliferation (42).”
BackgroundInhibition of SHP-1 activity by PKC-θ regulates NK cell activation threshold and cytotoxicity
Ben-Shmuel, A., Sabag, B., Puthenveetil, A., Biber, G., Levy, M., Jubany, T., Awwad, F., Roy, R. K., Joseph, N., Matalon, O., et al. (2022) · eLife · doi:10.7554/elife.73282 · Cited by 21
Stienne, C., Virgen‐Slane, R., Elmeń, L., Veny, M., Huang, S. X. L., Nguyen, J., Chappell, E., Balmert, M. O., Shui, J., Hurchla, M. A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110553 · Cited by 22
Self-citationBanerjee, A., Narasimhulu, C. A., & Singla, D. K. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00378.2023 · Cited by 23
BTLA exhibits immune memory for αβ T cells in patients with active pulmonary tuberculosis.
Zeng, J., Lin, D.-Z., Yi, L.-L., Liu, G.-B., Zhang, H., Wang, W.-D., Zhang, J., Wu, X.-J., Xiang, W.-Y., Kong, B., et al. (2014) · Europe PMC (PubMed Central) · Cited by 20
Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160
Shrestha, R., Garrett-Thomson, S. C., Liu, W., Almo, S. C., & Fiser, A. (2020) · Structure · doi:10.1016/j.str.2020.07.013 · Cited by 21
“Engagement of BTLA with HVEM induces phosphorylation of the BTLA immunoreceptor tyrosine-based inhibitory motif, resulting in recruitment of tyrosine phosphatases SHP1 and SHP2, which reduces cellular activation and growth (Gavrieli et al., 2003; Sedy et al., 2005; Watanabe et al., 2003).”
BackgroundInfluentialBTLA Expression and Function Are Impaired on SLE B Cells
Wiedemann, A., Lettau, M., Weißenberg, S. Y., Stefanski, A., Schrezenmeier, E. V., Rincón-Arévalo, H., Reiter, K., Alexander, T., Hiepe, F., Lino, A. C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.667991 · Cited by 20
“In BTLA-deficient B cells, slightly augmented responses to stimulation by anti-IgM were described (23).”
BackgroundSchilbach, K., Schick, J., Wehrmann, M., Wollny, G., Simon, P. D., Schlegel, P. G., & Eyrich, M. K. (2007) · Transplantation · doi:10.1097/01.tp.0000268074.77929.54 · Cited by 20
“PD-1 and PD-L1 (17), as well as the B- and Tlymphocyte attenuator (BTLA) and B7 (18) are expressed on T cells, APCs, or endothelial cells, respectively.”
BackgroundInuo, M., Ihara, K., Matsuo, T., Kohno, H., & Hara, T. (2009) · International Journal of Immunogenetics · doi:10.1111/j.1744-313x.2008.00809.x · Cited by 20
Cai, G., Wang, H., Qin, Q., Zhang, J., Zhu, Z., Liu, M., & Shen, Q. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp219 · Cited by 20
B7-H3: another molecule marker for Mo-DCs?
Zhang, G., Dong, Q.-M., Xu, Y., Yu, G., & Zhang, X. (2005) · PubMed · Cited by 20
Zhang, G. ‐., Dong, Q., Hou, J., Ge, Y., Ju, S., Lu, B., & Zhang, X. (2007) · Tissue Antigens · doi:10.1111/j.1399-0039.2007.00943.x · Cited by 20
Altering immune tolerance therapeutically: the power of negative thinking
Prud’homme, G. J. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0803394 · Cited by 20
“Conversely, inhibitory signals are delivered through CTLA-4/B7 [28–30], PD-1/PD-L1/L2 [31–38], and BTLA/B7x interactions [24].”
BackgroundKuncewicz, K., Battin, C., Sieradzan, A. K., Karczyńska, A. S., Orlikowska, M., Wardowska, A., Pikuła, M., Steinberger, P., Rodziewicz‐Motowidło, S., & Spodzieja, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228876 · Cited by 20
“The BTLA/HVEM or CD160/HVEM interaction delivers a co-inhibitory signal to T-cell activation, while the HVEM/LIGHT or HVEM/LTα binding leads to a co-stimulatory signal [1,2,15,16].”
Background
Metadata
- Authors
- Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., Murphy, T. L., Russell, J. H., Allison, J. P., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Boehringer Ingelheim (Germany) (DE)
- University of Perugia (IT)
- Washington University in St. Louis (US)
- Corresponding author
- Murphy, Kenneth M
- ORCID
- Venue
- Nature Immunology
- Published
- 2003-06-08
- Volume
- 4
- Issue
- 7
- Pages
- 670-679
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2118705059
- Cited by
- 883
- References
- 52
- Citations by year
- 2026: 26 · 2025: 30 · 2024: 38 · 2023: 38 · 2022: 38 · 2021: 59 · 2020: 56 · 2019: 49 · 2018: 35 · 2017: 29 · 2016: 31 · 2015: 36 · 2014: 34 · 2013: 41 · 2012: 37
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- BTLA, inhibitory receptors, T cell costimulation, CTLA-4, PD-1, SHP-1, SHP2, tyrosine phosphorylation, interleukin-2, T helper cell differentiation, B7 ligands, T cell proliferation, experimental autoimmune encephalomyelitis, antibody response
- MeSH terms
- Abatacept, Amino Acid Sequence, Animals, Antigens, Differentiation, Antigens, Surface, Encephalomyelitis, Autoimmune, Experimental, Interleukin-2, Lymphocyte Activation, Molecular Sequence Data, Phosphorylation, Proteins, Receptors, Immunologic, RNA, Messenger, T-Lymphocytes, Antigens, CD, Protein Tyrosine Phosphatases, B7-1 Antigen, Immunoconjugates, Intracellular Signaling Peptides and Proteins, Apoptosis Regulatory Proteins, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 6, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Protein Tyrosine Phosphatase, Non-Receptor Type 11, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.